Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Publisher Correction: Clinical development of cancer vaccines.

Nature medicine·2026

Same author

Social status impacts T-cell responses through synapse strength in the prefrontal cortex.

Cell research·2026

Same author

Clinical development of cancer vaccines.

Nature medicine·2026

Same author

Temporal and spatial composition of the tumor microenvironment predicts response to immune checkpoint inhibition in metastatic TNBC.

Nature cancer·2026

Same author

NEO-STIM advances personalized neoantigen-specific adoptive T cell therapy.

Nature communications·2026

Same author

MHC1-TIP enables single-tube multimodal immunopeptidome profiling and uncovers intratumoral heterogeneity in antigen presentation.

Communications biology·2026

Search research articles

Related Experiment Video

Updated: Jun 29, 2025

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

CD8-Targeted IL2 Unleashes Tumor-Specific Immunity in Human Cancer Tissue by Reviving the Dysfunctional T-cell Pool.

Paulien Kaptein¹, Nadine Slingerland¹, Christina Metoikidou¹

¹Division of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.

Cancer Discovery

|April 2, 2024

Summary

This summary is machine-generated.

A novel CD8-targeted IL2 fusion molecule (CD8-IL2) effectively reactivates dysfunctional tumor-specific CD8+ T cells. This approach shows promise for overcoming resistance to current cancer immunotherapies like PD-1 blockade.

More Related Videos

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Published on: January 14, 2011

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Related Experiment Videos

Last Updated: Jun 29, 2025

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Published on: January 14, 2011

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Area of Science:

Immunology
Cancer Biology
Molecular Therapy

Background:

Tumor-specific CD8+ T cells are crucial for antitumor immunity but often become dysfunctional within the tumor microenvironment.
Immune-checkpoint blockade (ICB) can restore T-cell function, but many patients do not respond, even with T-cell infiltration.

Purpose of the Study:

To explore a CD8-targeted Interleukin-2 (IL2) fusion molecule (CD8-IL2) for selective reactivation of intratumoral CD8+ T cells.
To assess the efficacy of CD8-IL2 in overcoming T-cell dysfunction and resistance to ICB.

Main Methods:

Utilized patient-derived tumor fragments to test the CD8-IL2 fusion molecule.
Investigated the ability of CD8-IL2 to reactivate dysfunctional CD8+ T cells in the tumor microenvironment.
Compared the effects of CD8-IL2 with PD-1 blockade.

Main Results:

CD8-IL2 treatment broadly enhanced the effector capacity of intratumoral CD8+ T cells.
Reactivation of dysfunctional T cells by CD8-IL2 required simultaneous antigen recognition and was superior to PD-1 blockade.
CD8-IL2 functionally reinvigorated T cells in tumors resistant to anti-PD-1 therapy.

Conclusions:

CD8-IL2 selectively reactivates dysfunctional CD8+ T cells, enhancing antitumor immunity.
This approach offers a potential novel treatment strategy for cancer patients, particularly those resistant to existing immunotherapies.